S&P Futures
3,790.25+28.00(+0.74%)Dow Futures
30,932.00+212.00(+0.69%)Nasdaq Futures
12,908.25+106.00(+0.83%)
OraSure Technologies, Inc. (OSUR)
Chart Events
Performance Outlook
| Previous Close | 12.86 |
| Open | 12.90 |
| Bid | 0.00 x 1200 |
| Ask | 13.43 x 1100 |
| Day's Range | 12.73 - 13.25 |
| 52 Week Range | 5.23 - 19.75 |
| Volume | 697,927 |
| Avg. Volume | 1,517,817 |
| Market Cap | 926.788M |
| Beta (5Y Monthly) | 0.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.22 |
| Earnings Date | Feb 17, 2021 - Feb 22, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.86 |
- Zacks
Aphria (APHA) Looks Good: Stock Adds 6% in Session
Aphria (APHA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- GlobeNewswire
OraSure Technologies Announces 2021 Annual Meeting Date
BETHLEHEM, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2021 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 18, 2021. The record date for the Meeting will be March 26, 2021. Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2021 Annual Meeting, or any adjournment(s) or postponement(s) of the Meeting. This will be a completely virtual meeting, conducted as a live webcast. Further details regarding the Meeting will be provided at a later date. About OraSure TechnologiesOraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers.For more information on OraSure Technologies, please visit www.orasure.com.Investor Contacts: Sam Martin, Argot Partners 212-600-1902 OraSure@argotpartners.comRoberto Cuca, Chief Financial Officer (610) 882-1820 investorinfo@orasure.com
- GlobeNewswire
OraSure Technologies to Present at the 39th Annual J.P. Morgan Healthcare Conference
BETHLEHEM, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the 39th Annual J.P. Morgan Healthcare Conference. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on January 12, 2021, at approximately 2:50 PM Eastern Standard Time (11:50 PM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. A replay of the webcast will be available on OraSure Technologies’ web site for 14 days. Alternatively, you can access the live webcast of the presentation via the following link: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35224-orasure-technologies-inc/webcast?gpu_only=true&kiosk=true.About OraSure TechnologiesOraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand), UrSure and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.Company contacts: Sam Martin Argot Partners 212-600-1902 OraSure@argotpartners.comJeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com www.orasure.com
